Alla studier
RekryteringObservationsbaserad

Protein engineering to design better enzyme replacement therapies for Fabry disease

This study is looking into new, improved treatments for Fabry disease, a rare inherited condition. Current treatments, called enzyme replacement therapies, can have side effects and aren't always fully effective. Researchers are using artificial intelligence to design new enzymes that they hope will work better, cause fewer immune reactions, and be needed less often. If you have Fabry disease and are over 16, you could take part by providing blood and urine samples. You might also be asked to wear a blood pressure monitor at home. While there are no direct health benefits to you, your contribution will help develop better treatments for Fabry disease in the future. The study is run by the University of Edinburgh.

Överblick

Status
Rekrytering
Sponsor
Universitetet i Edinburgh
Inskrivningsmål
30
Starta
01 Aug 2024
Beräknad slutförande
30 dec 2026

Vad handlar denna studie om?

Fabry disease is a rare condition that's passed down through families. It happens when certain enzymes in the body don't work properly, leading to a build-up of harmful substances in cells. This can damage many parts of the body, including the heart, kidneys, blood vessels, and nervous system, causing problems like pain, strokes, and organ damage.

Currently, some people with Fabry disease are treated with 'enzyme replacement therapy' (ERT). This involves getting regular infusions (treatment given directly into a vein). However, these treatments aren't perfect; they don't always work as well as the body's natural enzymes, can't reach all affected areas, and sometimes cause allergic reactions. These reactions can also make the treatment less effective over time. Patients often find the frequent infusions and potential side effects quite challenging.

This study is trying to find better ways to treat Fabry disease. Researchers are using clever technology, including artificial intelligence, to design new enzymes. The aim is for these new enzymes to work more effectively, have fewer side effects (especially fewer immune reactions), and potentially be given less often. The first step is to test how these new enzymes interact with patient blood samples in the lab, to see if they are less likely to trigger an immune response compared to existing treatments.

Viktiga punkter

  • Researchers are creating new, potentially better treatments for Fabry disease.
  • This study tests these new treatments in lab samples, not directly in patients.
  • You can take part by providing blood and urine samples during a routine clinic visit.
  • Participation helps future patients, though there are no direct benefits to you.
  • The study involves minimal risk, like routine blood tests or wearing a monitor.
  • It's open to people with Fabry disease over 16, not on immune-suppressing drugs or gene therapy.

Vem kan vara berättigad?

This study is looking for people who have been diagnosed with Fabry disease, either through a blood test or genetic testing. You need to be 16 years old or older to take part, and there's no upper age limit.

To make sure the study results are clear, you cannot take part if you are currently on medicines that suppress your immune system (like those used after an organ transplant), or if you've already had 'gene therapy' for Fabry disease. This is because these treatments might affect how your body responds to the new enzymes being tested.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. I have a diagnosed form of Fabry disease.
  2. I am 16 years old or older.
  3. I am not taking any regular immune-suppressing medications.
  4. I have never received experimental gene therapy for Fabry disease.
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you decide to take part, you'll be asked to provide extra blood and urine samples. This can usually be done at the same time as your routine blood tests during a visit to your NHS clinic, making it as convenient as possible. You might also be given the option to wear a special monitor for 24 hours at home. This monitor painlessly checks your blood pressure and how your blood vessels are working. After 24 hours, you'll simply post it back to the research team. The study isn't about giving you new medication; it's focused on collecting samples to test new treatments in the laboratory.

Potentiella risker och fördelar

There are no direct health benefits for you personally by taking part in this study, but your contribution is vital. It will help researchers understand Fabry disease better and develop improved treatments for others in the future. The risks are very small: blood tests can cause slight discomfort or a small bruise, but these will be taken with your usual clinic samples. The 24-hour blood pressure monitor is worn outside your body and might be a little inconvenient, but it shouldn't cause pain. You are completely free to withdraw from the study at any time without giving a reason, and this won't affect your medical care.

Platser (1)

  • Universitetet i Edinburgh
    Ungefärlig
    Edinburgh, Scotland

Vanliga frågor

Vad är Fabrys sjukdom?

Fabry disease is a rare inherited condition where certain enzymes don't work properly, causing harmful substances to build up in the body and damage organs like the heart and kidneys.

What are the new treatments being developed?

Researchers are designing new enzymes using artificial intelligence. The goal is for these new enzymes to work better and cause fewer side effects than current treatments.

Do I need to take any new medicine if I join?

No, this study does not involve taking any new medicines. It focuses on collecting blood and urine samples to test new treatments in the lab.

Will I get any money for taking part?

The information provided does not mention any payment for participation. It's a voluntary contribution to research.

Hur länge kommer studien att pågå?

The study is running from August 2024 to December 2026, but your personal involvement will likely be a single visit for samples and potentially some home monitoring.

Hur du får reda på mer

Eve Miller-Hodges

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Intresserad av att delta?

Registrera ditt intresse

Dela dina uppgifter och forskarteamet för "Protein engineering to design better enzyme replacement ther…" kommer att kontakta dig om du kan vara berättigad. Prata alltid med din läkare innan du går med på att delta.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.